Illumina (ILMN) wins its motion for dismissal in its patent litigation with Helicos BioSciences (HLCS), which was filed against the company in October 2010. The judge ruled the patent was invalid for inadequate written description. It was the last remaining one to be dismissed by the court, out of three separate patents originally asserted by Helicos in the lawsuit.
Helicos BioSciences (HLCS) +81% early on after a New York Times article highlights how its technology vastly simplifies decoding the human genome. Dr. Stephen Quake, who founded Helicos, says the much-discussed goal of the $1,000 genome could be as little as 2-3 years away.
HLCSQ.OB - very active, we could see rip to 3.75 intraday
View all 0 replies
HLCSQ vs. ETF Alternatives
Helicos BioSciences Corporation is a life sciences company focused on innovative genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. Our products are based on our proprietary True Single Molecule Sequencing (tSMS)™ technology which enables rapid...More